We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0A50 market cap is 0. The company's latest EPS is USD -1.1907 and P/E is -0.96.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 215k | 74.55M | 97.89M | 34.22M | 6.81M |
| Operating Income | -5.89M | 41.69M | 46.07M | -26.98M | -42.61M |
| Net Income | -6.19M | 42.48M | 36.66M | -14.24M | -36.41M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.22M | 71.24M | 160.03M | 123.09M | 95.32M |
| Total Liabilities | 478k | 4.54M | 25.56M | 8.57M | 9.31M |
| Total Equity | 1.74M | 66.7M | 134.48M | 114.52M | 86.01M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -5.53M | 28.17M | 41.08M | 6.57M | -22.08M |
| Investing | -435k | -5.82M | 4.1M | -58.17M | 15.39M |
| Financing | 5.9M | 19.74M | 450k | -14.03M | -1.36M |
| Market Cap | 0 |
| Price to Earnings Ratio | -0.96 |
| Price to Sales Ratio | 5.12 |
| Price to Cash Ratio | 2.34 |
| Price to Book Ratio | 0.41 |
| Dividend Yield | - |
| Shares Outstanding | 30.58M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Co-diagnostics Inc |
| Address |
2401 s. foothill drive salt lake city, utah 84109 |
| Website | https://www.codiagnostics.com |
| Industry | surgical,med instr,apparatus (3841) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
